Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of test reagents in the preparation and evaluation of drugs for clinical treatment monitoring of clinical tumor patients

A technology for tumor patients and clinical treatment, applied in the field of enzyme activity detection, can solve the problems of no public tumor treatment detection, no ultra-early tumor early warning monitoring, etc.

Active Publication Date: 2017-05-03
WUHAN SHANGYI HEALTH SCI & TECH CORP +3
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the prior art, the evaluation reagents for cancer (such as lung cancer, cervical cancer, breast cancer, and nasopharyngeal cancer) did not carry out early warning and monitoring for ultra-early tumors, and did not disclose the treatment and detection of postoperative tumors.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of test reagents in the preparation and evaluation of drugs for clinical treatment monitoring of clinical tumor patients
  • Application of test reagents in the preparation and evaluation of drugs for clinical treatment monitoring of clinical tumor patients
  • Application of test reagents in the preparation and evaluation of drugs for clinical treatment monitoring of clinical tumor patients

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0093] Determination of thioredoxin reductase activity in blood:

[0094] 1. Determination conditions of microplate reader

[0095] In the mode controlled by Ascent Software Version2.6,

[0096] Oscillation: time 5s, speed 1020rpm;

[0097] Measurement mode: continuous;

[0098] Measurement Type: Dynamic;

[0099] Time interval: 30s;

[0100] Number of measurements: 15;

[0101] Wavelength: 405nm.

[0102] When analyzing an actual blood sample, a standard curve is established for each analysis run to calculate the concentration of the analyte in the analysis run.

[0103] 2. Measurement process

[0104] 2.1 Preparation of working solution: Mix 1M K2HPO4615ml and 1M KH2PO4385ml, adjust the pH to 7.0, add EDTA2924mg, BSA200mg, dissolve, and store at 4°C.

[0105] 2.2 Preparation of inhibitor working solution (25 μl): Dilute 20 mM compound I stock solution to 25 μM with working solution, and store at 4° C. in the dark.

[0106] 2.3 Turn on the microplate reader to prehea...

Embodiment 2

[0116] Kits for the determination of thioredoxin reductase activity in blood:

[0117] Test kit of the present invention may contain:

[0118] 1. DTNB powder 49.8mg, protected from light, stored at room temperature;

[0119] 2. NADPH powder 4.2mg, protected from light, stored at -20°C;

[0120] 3. 10×working solution (1M potassium phosphate buffer, pH=7.4, containing 73.1mg EDTA, 5mg BSA.) 2mL, store at 4°C;

[0121] 4. TrxR inhibitor solution (containing 2.5mM inhibitor selected from one of the compounds I-XI), 100uL, stored at -20°C;

[0122] 5. Positive control: rat liver TrxR, 300U / mg XX Unit, stored at -20°C;

[0123] 6. TNB standard;

[0124] The detection reagent can be used for 100 tests;

[0125] The using method of kit of the present invention:

[0126] 1. Take 2mL of 10× working solution (0.5M potassium phosphate buffer, pH7.4) and dilute to 20mL with deionized water (containing 73.1mg ethylenediaminetetraacetic acid (EDTA), 5mg bovine serum albumin (BSA) )) ...

Embodiment 3

[0141] 1. Detection data of TR activity in normal group and tumor group

[0142] Table 2 Statistics of TR activity detection data in normal group and tumor group

[0143]

[0144]

[0145] 2. Comparison test between normal group and tumor group (comparison test of two normal samples) F test

[0146] TR (正常) ~N(μ TR(正常) , σ 2 TR(正常) )

[0147] TR (肿瘤) ~N(μ TR(肿瘤) , σ 2 TR(肿瘤) )

[0148] F=(S 2 TR(肿瘤) / σ 2 TR(肿瘤) ) / (S 2 TR(正常) / σ 2 TR(正常) )≈S 2 TR(肿瘤) / S 2 TR(正常) ~F(n (肿瘤) -1,n (正常) -1)

[0149] Calculate F=S 2 TR(肿瘤) / S 2 TR(正常)

[0150] Judgment F﹤F α / 2 (n (肿瘤) -1,n (正常) -1), P>α, no significant difference between the two

[0151] Judgment F≥F α / 2 (n (肿瘤) -1,n (正常) -1), P<α, there is a significant difference between the two

[0152] Table 3 Comparison test between normal group and tumor group

[0153]

[0154] 3. Comparison test between normal group and tumor group (comparison test of two normal samples) u test

[0155] Means com...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
wavelengthaaaaaaaaaa
Login to View More

Abstract

The invention provides an application of a detection reagent in preparation of drugs for evaluation of clinical tumor patient clinical treatment monitoring; the detection reagent includes the components respectively independently existing: (a) a reagent determining the total sulfydryl content in a sample; and (b) a thioredoxin reductase specific inhibition compound. Clinical treatment includes all kinds of clinical chemotherapies, radiation therapies or other clinical treatment schemes. The detection reagent has obvious activity difference on different treatment stages (such as preoperation, intraoperation and postoperation) and clinical effects (CR, PR, SD and PD) of lung cancer, breast cancer, nasopharyngeal carcinoma and cervical carcinoma, and data analysis display has a statistical significance, therefore, the detection reagent determines the tumor treatment effect through TR activity detection and dynamically monitors the process of related diseases, so that the detection reagent provides great guiding significance on different treatment stages of patients and can be used in clinic.

Description

technical field [0001] The invention belongs to the field of enzyme activity detection, and relates to the application of a test reagent in the preparation and evaluation of medicines for clinical treatment monitoring of clinical tumor patients. The tumors include lung cancer, cervical cancer, breast cancer, and nasopharyngeal cancer. The clinical treatment includes For various clinical chemotherapy, radiotherapy or other clinical treatment options. Background technique [0002] In my country, about 2 million people suffer from cancer every year, and 1.5 million people die of cancer, and it is still increasing, and it is gradually showing a younger trend. The direct economic loss caused by cancer to our country exceeds 100 billion yuan every year (excerpted from Beijing Morning Post 2007 / 03 / 31). According to the report of the Ministry of Health in 2007, the number of deaths due to tumors in my country has reached 1.8 million by 2006, which is 300,000 higher than that in 200...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/26
Inventor 曾慧慧
Owner WUHAN SHANGYI HEALTH SCI & TECH CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com